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Cognitive and Psychiatric Predictors to Psychosis in
Velocardiofacial Syndrome: A 3-year follow-up study
Kevin M. Antshel, Ph.D., Robert Shprintzen, Ph.D., Wanda Fremont, M.D., Anne Marie
Higgins, NP, Stephen V. Faraone, Ph.D., and Wendy R. Kates, Ph.D.
State University of New York - Upstate Medical University
Abstract
Objective—To predict prodromal psychosis in adolescents with velocardiofacial syndrome
(VCFS).
Method—70 youth with VCFS, 27 siblings of youth with VCFS and 25 community controls were
followed from childhood (Mean age = 11.8 years) into mid-adolescence (mean age 15.0 years).
Psychological tests measuring intelligence, academic achievement, learning/memory, attention and
executive functioning as well as measures of parent and clinician ratings of child psychiatric
functioning were completed at both time points.
Results—Major depressive disorder, oppositional defiant disorder and generalized anxiety disorder
diagnoses increased in the VCFS sample. With very low false positives, the best predictor of
adolescent prodromal psychotic symptoms was parent ratings of childhood odd/eccentric symptoms
and child performance on a measure of executive functioning, the Wisconsin Card Sorting Test.
Conclusions—Similar to the non-VCFS prodromal psychosis literature, a combination of
cognitive and psychiatric variables appears to predict psychosis in adolescence. A child with VCFS
who screens positive is noteworthy and demands clinical attention.
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Velo-cardio-facial syndrome (VCFS) is caused by an interstitial deletion from chromosome
22 at the 22q11 band. The most common microdeletion syndrome yet identified in humans,
VCFS has a population prevalence of approximately 1:2000 to 1:6000 live births 1, 2. In most
cases, VCFS is caused by a hemizygous deletion of 3 million base pairs of DNA encompassing
40 genes but approximately 8% have smaller nested deletions of 1.5 million base pairs spanning
34 genes 3. Structural anomalies affect nearly every part and system of the body and may
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include congenital heart disease, palatal defects, thymic hypoplasia, and endocrine disorders
1. VCFS is the most common genetic cause of conotruncal heart anomalies and the most
common genetic cause of cleft palate 4.
VCFS is associated with a distinctive cognitive phenotype. Full scale IQ’s are commonly in
the Borderline range of functioning (IQ 70–75) 5–11. Reading, spelling and phonological
processing skills as well as rote auditory/verbal memory are relatively spared in VCFS 5, 11–
17. Conversely, math learning disabilities 5, 11, 12, 17–22, visuospatial deficits 14, 17, 18, attention
deficits 11, 19, 23, 24 and executive function deficits in domains such as cognitive flexibility,
response inhibition and nonverbal working memory have been reported to be an area of
weakness in the VCFS cognitive profile 11–13, 15–17, 19, 25–28.
The most commonly reported psychiatric disorders are attention deficit/hyperactivity disorder
(ADHD) (present in 30–40% of individuals with VCFS) 29–31, anxiety disorders, especially
simple phobias and separation anxiety (present in 30–40%) 10, 30, 32, 33, autism spectrum
disorders (10–30%) 34, 35, mood disorders including major depression and bipolar disorder
(present in 20–30%) 30, 36 and psychotic disorders (25–30%) 37, 38.
Clearly, the most worrisome feature of the VCFS behavioral profile is the elevated risk for
schizophrenia and psychosis. The age of onset varies between early adolescence and early
adulthood, with most onsets occurring in the late teens and early 20’s 39–41. More mild,
subthreshold psychotic symptoms occur in 30–50% of youth with VCFS 10, 42. Unlike many
psychiatric disorders (e.g., ADHD, anxiety, depression, etc.), the increased risk for
schizophrenia appears more specific to VCFS rather than a function of developmental delays.
In other words, individuals without VCFS who have mental retardation/developmental delays
have more symptoms of psychopathology such as inattention, hyperactivity, anxiety, etc. than
average IQ individuals 43; psychotic symptoms, however, are not generally elevated in the non-
VCFS mental retardation/developmental disorder population 43.
The catechol-O-methyltransferase (COMT) gene is located on chromosome 22q11. The
COMT gene is located in the 1.5 Mb VCFS microdeletion region. Thus all individuals with
this disorder have only one copy of this gene, suggesting that COMT may be a candidate gene
for psychosis in VCFS. The Val-108/158-Met COMT polymorphism has received empirical
attention as a possible risk factor for psychosis. This polymorphism has been associated
robustly with prefrontal cognitive functions in typical children 44 and adults 45. Homozygosity
for the Met allele is associated with optimal cognitive function, evidence for its association
with psychosis is more variable 46. However, findings from studies of the effect of COMT
polymorphisms on cognition and psychosis in VCFS have not been consistent. Whereas a study
by Gothelf and colleagues 47 suggested that individuals with VCFS who have the low-activity
(Met) allele of the COMT gene had a more significant decline in Verbal IQ scores and had
more severe psychotic symptoms than those carrying the high-activity (Val) allele, other
studies have found either the opposite 48 or no 49, 50 effect of COMT on cognition and
psychosis.
Only one longitudinal study of youth with VCFS has been published. Those findings suggested
that at Time 1 (late childhood), subthreshold psychotic symptoms, anxiety (especially OCD)
and depression symptoms, and lower verbal IQ scores predicted the onset of psychotic disorders
in adolescence 47. The purpose of the present investigation was to attempt to replicate these
data using a larger sample with more neuropsychological and psychiatric dependent variables.
Given the greatly elevated risk for psychosis, the substantial percentage of children and
adolescents with VCFS who have ADHD, major depressive disorder, anxiety disorders and
oppositional defiant disorders and the relative frequency of VCFS, a study of VCFS seems an
important topic for child and adolescent psychiatrists. Moreover, given both the importance of
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early intervention in psychosis 51 and the critical shortage of child and adolescent psychiatrists
52, efforts to predict psychosis in the VCFS population seem clinically-relevant.
Method
Participants
Participants were enrolled in the longitudinal study of risk factors for psychosis in VCFS. At
time 1, 80 youth with VCFS (Mean age = 11.9 years, SD = 2.2), 33 siblings of youth with
VCFS (sibling control; Mean age = 12.2 years, SD = 1.9) and an age, gender and socioeconomic
status matched group of 40 non-VCFS youth (community control; Mean age = 12.0 years, SD
= 1.9) participated. No age differences existed between the groups at Time 1, F (2, 158) = 0.24,
p = .784, η2 = .01.
At Time 2, 70 youth with VCFS (Mean age = 15.0 years, SD = 2.1), 27 siblings of youth with
VCFS (Mean age = 15.0 years, SD = 1.9) and 25 community controls (Mean age = 14.7 years,
SD = 1.4) were included in the analyses. No age, F (2, 120) = 0.44, p = .647, η2 = .01, or gender
differences, χ2 (df = 2) = 0.9, p = .641, existed between the groups at Time 2. Please see Table
1 for complete participant information.
An independent samples t-test indicated that there were no differences in attrition between our
three groups, t (2) = 3.06, p = .263. Furthermore, participants lost to follow-up did not differ
from those who did follow-up on any relevant Time 1 sociodemographic measures including
participant age, gender, and socioeconomic status. In addition, participants lost to follow-up
did not differ from those who did follow-up on any relevant Time 1 psychiatric or cognitive
variables. Thus, those participants who completed Time 2 assessments appear representative
of the broader Time 1 sample.
Procedures
Participants were assessed at two time points, with approximately three years between time
points. At Time 2, all involved research personnel were blinded to Time 1 findings. Informed
consent/assent was obtained from parents and children under protocols approved by the
institutional review board.
Each child enrolled in the study was administered a neuropsychological test battery that
included tests of cognitive function, academic achievement, executive function, sustained
attention, working memory and learning. Psychological testing was followed by a structured
psychiatric interview, administered by a clinical psychologist or a board-certified child
psychiatrist. After completing the psychological and psychiatric assessments, the participating
children had a magnetic resonance imaging (MRI) scan of his or her brain. Finally, all VCFS
participants had a blood draw. This blood sample and resulting DNA sample was processed to
genotype the COMT Val-108/158-Met COMT polymorphism. Our genotyping methods have
been previously described in full detail elsewhere 53.
Cognitive and Psychiatric Assessment Tools
Unless otherwise noted, all instruments were administered at both Time 1 and 2.
Cognitive—Measures of general intellectual functioning were the Wechsler Intelligence
Scale for Children —Third edition (WISC-III) 54 or Wechsler Adult Intelligence Scale – Third
edition (WAIS-III) 55. The WISC-III was administered to all participants at Time 1, and to
participants at or under the age of 16 years, 11 months at Time 2. The WAIS-III was
administered to all participants over the age of 16–11 at Time 2. Comparative studies between
the Wechsler child and adult intelligence scales suggest that relative to WISC-III scores, WAIS-
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III scores are inflated between three and seven points 56–58. Accordingly, for our data analyses,
we subtracted five points from WAIS-III full-scale, verbal and performance IQ scores.
Academic achievement was assessed using the Wechsler Individual Achievement Test-Second
edition(WIAT-II) 59. Attention was assessed using the Gordon Diagnostic System - Continuous
Performance Test (CPT) 60. Executive functioning was assessed with the Wisconsin Card
Sorting Test (WCST) 61 and Tower of London (TOL).
Learning and memory was assessed with the California Verbal Learning Test (CVLT) 62 and
the Visual Span Test 63. (The Visual Span is a computer-presented adaptation of the Visual
Memory Span subtest of the Wechsler Memory Scale-Third Edition, produced on the Colorado
Assessment Tests. An irregular array of squares is displayed on the screen, a subset of them is
illuminated briefly, and the subject must reproduce these sequences of increasing length.
Forward and backward span scores are obtained.)
Psychiatric—The Schedule for Affective Disorders and Schizophrenia for School-Age
Children-Present and Lifetime Version (K-SADS-PL) 64 was utilized to make DSM-IV 65
psychiatric diagnoses. The child’s primary caregiver (almost always his/her mother) was
interviewed with the K-SADS-PL. Every attempt was made to interview the child, but in many
cases the child had difficulty responding; in these cases, the K-SADS-PL data was based on
the parent’s response. A child and adolescent psychiatrist or clinical child psychologist
administered the KSADS assessment. Inter-rater reliability, which was calculated for 10
interviews, and assessed with the Kappa coefficient, was .91.
The Scale of Prodromal Symptoms (SOPS) 66 was used to assess prodromal psychotic
symptoms. The SOPS consists of four domains, in which the clinician rates (based on self-
report and observation) each participant and derives summary scores for positive prodromal
symptoms (e.g., grandiosity, hallucinations) negative prodromal symptoms (e.g., withdrawal,
avolition), disorganization (e.g., odd behavior, bizarre thought) and general symptoms (e.g.,
sleep disturbance, dysphoric mood). The SOPS was administered to all participants at Time 2
by a doctoral-level clinician during the structured psychiatric interview. Inter-rater reliability,
based on five SOPS interviews and assessed with the intraclass correlation coefficient, was
0.90. Since many of the children in our study had difficulty responding to a psychiatric
interview, we reworded the questions in this scale to allow us to administer it to the child’s
parent. Ratings were based on a Likert-type scale, with scores that ranged from zero to four
for each symptom. Summary scores for the four symptom domains were calculated. Our
primary reason for utilizing the SOPS was to predict prodromal symptoms; thus, we only used
the summary scores from the positive, negative and disorganization subscales. Our SOPS Total
scores are based upon the aggregate of these three subscales. In addition, given that positive
symptoms are the most specific to psychosis, several of our analyses used this subscale as an
outcome measure. Using a method with a precedent in the literature 66, we identified positive
prodromal symptoms as one or more of the five SOPS positive symptom items as being rated
a ‘2’ or higher.
The Premorbid Adjustment Scale (PAS) 67 evaluates the achievement of developmental goals
from childhood into adulthood in persons who eventually develop schizophrenia. Although
the scale was originally designed as a retrospective instrument to assess premorbid functioning
up to six months prior to a psychiatric hospitalization, we used the scale prospectively, rating
each participant on the items corresponding to his or her current age. The scale focuses on five
areas of functioning: social accessibility-isolation; peer relationships; school functioning;
ability to function outside the nuclear family; and the capacity to form intimate socio-sexual
ties. Ratings were based on data obtained during the K-SADS-PL. Ratings for each item were
anchored to descriptive phrases, ranging from 0 (representing “healthiest” functioning) to 6
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(representing most impaired functioning). Ratings were summed and then divided by the total
number of items, producing a ratio ranging from 0 (healthy functioning) to 1 (poor functioning).
Inter-rater reliability, for ten participants between two doctoral level raters, calculated using
an intraclass correlation coefficient of item ratings, ranged from .85 to .90.
Finally, the Behavior Assessment Scale for Children (BASC) – Parent report version 68 was
administered to provide a continuous measure of adaptive and problem behaviors. Each of the
130 items of the child version of the BASC is rated on a 4-point frequency scale, ranging from
never to almost always.
Data Analyses
To create a standard metric across all psychological tests, all scores were converted to z-scores.
Changes in performance as a function of time were calculated by subtracting Time 1
performance (z-score) from Time 2 performance (z-score). Thus, positive values indicate
stronger performance at Time 2.
McNemar non-parametric tests for related samples were computed to compare KSADS
diagnostic consistency across time. Separate tests were computed for each sample. Then, to
analyze between group changes across time, a logistic regression for each psychiatric diagnosis
was computed using Time 2 psychiatric diagnosis as the outcome measure and Time 1
diagnosis by group interaction as the predictor.
Repeated-measures multivariate analyses of variance (MANOVA) models, with diagnostic
group as the main effect, and psychological test scores or behavioral variables and time as
repeated factors were computed. Group and time effects and group-by-time interaction were
examined. In order to test the association between SOPS scores and behavioral/cognitive
variables, we conducted Zero-inflated Poisson regression analyses 69. The choice of the
Poisson regression was based on the distribution of our SOPS data, for which at least 50% of
scores equaled zero (indicating the absence of any prodromal symptoms). We initially
performed the Vuong test in order to determine if the proportion of scores equaling zero
warranted the traditional Poisson regression analysis or the zero-inflated Poisson regression
analysis. Based on the results of the Vuong test, we conducted the zero-inflated Poisson
analysis for all variables of interest (using Stata 10.0). Finally, sensitivity, specificity, negative
predictive power (NPP) and positive predictive power (PPP) analyses were conducted to help
determine the clinical utility of a measure to predict psychosis.
Results
Longitudinal Changes in Psychiatric Status
At Time 1, the most common psychiatric diagnoses in the VCFS sample were ADHD, major
depressive disorder, phobias and generalized anxiety disorder. As demonstrated in Table 1,
four Axis I conditions changed across time within the VCFS sample. Major depressive disorder
(p < .001), oppositional defiant disorder (p = .008) and generalized anxiety (p =. 040) diagnoses
increased in prevalence. No youth with VCFS who had a Time 1 major depressive disorder,
oppositional defiant disorder or generalized anxiety diagnosis lost their diagnosis at Time 2.
Thus, the differences were due to additional youth with VCFS acquiring the diagnosis at Time
2. In the sibling group, the one participant who had a Time 1 major depressive disorder
diagnosis maintained the diagnosis at Time 2; in addition, 7 sibling participants who did not
have a Time 1 major depressive disorder diagnosis had a Time 2 diagnosis (p = .032).
No controls or siblings gained an ADHD diagnosis; although approaching significance (p = .
094), 7 of 15 control participants who had a Time 1 ADHD diagnosis did not have a Time 2
ADHD diagnosis. Two of the 4 sibling participants who had a Time 1 ADHD diagnosis did
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not have a Time 2 ADHD diagnosis (p = .125). In the VCFS sample, 12 of the 36 participants
who had a Time 1 ADHD diagnosis did not have a Time 2 ADHD diagnosis (p = .096).
However, unlike the sibling and control samples, five youth with VCFS had a Time 2 ADHD
diagnosis yet not a Time 1 ADHD diagnosis. See Table 1 for complete KSADS data and
McNemar analyses.
To assess between group changes, logistic regressions were computed using Time 2 psychiatric
diagnosis as the outcome measure and Time 1 diagnosis by group interaction as the predictor.
To limit our number of analyses, mood and anxiety disorders were considered collectively, yet
are reported in Table 1 individually. Two psychiatric diagnostic categories had psychiatric
diagnosis × group interactions; mood disorders increased in the VCFS and sibling groups
relative to the control group, Wald χ2 = 11.43, p < .001, and anxiety disorders increased VCFS
group relative to both other groups, Wald χ2 = 6.03, p = .018.
Longitudinal Changes in Cognition
As shown in Table 2, several Time × Study Group psychological test performance interactions
emerged on measures of intelligence, on the full scale, verbal comprehension and perceptual
organization indices, community controls improved more robustly than both VCFS and sibling
control participants. On the academic measure, only the VCFS group improved in reading. On
the Visual Span, control participants improved by one-half of a standard deviation, whereas
sibling controls showed no change and VCFS participants decreased slightly. On the WCST,
both VCFS and sibling participants improved on perseverative error performance while
controls did less well. No interactions emerged on the CVLT, Continuous Performance Test
and Tower of London. All groups did less well at Time 2 on the CVLT, although declines in
scores were sharper for sibling and VCFS participants than for controls. All study groups
improved from Time 1 to Time 2 on the Continuous Performance Test and Tower of London.
Complete results are detailed in Table 2.
Multiple time × gender interactions occurred; across several psychological tests, female
performance declined more than males. However, no time × gender × diagnosis interactions
emerged.
Longitudinal Changes in Behavior
As shown in Table 3, no interactions emerged on the parent report of child behaviors on the
BASC as a function of time. Additionally, no time × gender × diagnosis interactions emerged.
Predicting Time 2 Prodromal Symptoms From Time 1 Cognitive and Behavioral/Psychiatric
Variables
At Time 2, no sibling controls and one community control had any positive or disorganized
prodromal symptoms. Given our lack of prodromal symptoms in both control groups, analyses
predicting prodromal symptoms only included VCFS participants. See Table 4 for SOPS total
scores and subscales (positive, negative, disorganized) for each of the three groups (VCFS,
siblings and community controls)
As shown in Table 5, several Time 1 psychological test variables predicted Time 2 prodromal
symptoms. In order of predictive power, Time 1 performance on the Visual Span Backward,
WISC-III Verbal Comprehension Index, WISC-III Processing Speed Index, Visual Span
Forward, WCST Perseverative Errors Standard Score and Stroop Color-Word Interference T-
Score all significantly predicted Time 2 prodromal symptoms. Across all psychological tests,
lower performance at Time 1 predicted more Time 2 prodromal symptoms.
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Behaviorally, as seen in Table 3, higher Time 1 levels of odd/eccentric and anxious behaviors
were significant BASC predictors of prodromal symptoms at Time 2. Lower clinician ratings
on the CGAS and PAS at Time 1 were also significant predictors of Time 2 prodromal
symptoms.
Predicting Positive Prodromal Symptoms Time 1 Variables
Given the specificity of positive symptoms towards a diagnosis of a psychotic disorder, we
recomputed our Poisson regression models using SOPS positive symptoms as the outcome
variable and Time 1 cognitive and behavioral variables as predictors. In order of predictive
power, the WCST Nonperseverative Error Standard Score (z = −3.25, p < .001), the Tower of
London Total Number of Moves (z = 2.18, p = .029) and CPT number of errors of omission
(z = 2.18, p = .029) were significant predictors of Time 2 positive symptoms. Across all three
psychological tests, worse performance at Time 1 was predictive of higher number of SOPS
positive symptoms at Time 2.
Behaviorally, the Time 1 BASC Atypicality Scale (z = 3.55, p < .001) and the PAS (z = 3.71,
p = .002) were both significant predictors of Time 2 SOPS positive symptoms.
Impact of Val/Met Status on Prodromal Symptoms
In our VCFS sample, all of whom were deleted for one copy of the COMT gene, 39 of the
participants had the Val allele on the intact chromosome 22 and 23 had the Met allele. There
were no age differences between youth with the two alleles, F (1, 66) = 0.14, p = .871, eta2 = .
00. More males have the Val allele (n = 17) and more females (n = 24) have the Met allele,
χ2 = 7.63, p = .022. There were no differences between SOPS prodromal symptoms and Val
and Met allele status, F (1, 66) = 0.71, p = .402, eta2 = .01.
Predicting Time 2 Major Depressive Disorder Diagnosis From Time 1 Variables
Given that 64% of our VCFS and 30% of our sibling participants met DSM-IV diagnostic
criteria for a major depressive disorder diagnosis at Time 2, we sought to examine Time 1
variables which may be significant predictors. No Time 1 cognitive or behavioral variables
predicted a Time 2 major depressive disorder diagnosis in the sibling group.
In the VCFS group, two Time 1 cognitive variables significantly predicted a Time 2 major
depressive disorder diagnosis: WISC-III Processing Speed (Wald χ2 = 5.45, p = .011) and
Visual Span Backward (Wald χ2 = 4.87, p = .020). Several Time 1 behavioral and psychiatric
variables predicted a Time 2 major depressive disorder diagnosis (in order of predictive power):
BASC Anxiety (Wald χ2 = 14.02, p < .001), BASC Withdrawal (Wald χ2 = 12.44, p < .020),
BASC Social Skills (Wald χ2 = 11.76, p < .001), a Time 1 ADHD diagnosis (Wald χ2 = 9.87,
p < .001) and CGAS (Wald χ2 = 5.54, p = .023).
Sensitivity/Specificity/PPP/NPP
Using a criterion with a precedence in the literature 66, we grouped participants with VCFS
into two groups: those with significant positive prodromal symptoms (n= 14) and those without
(n = 56). Using the highest predictor of the SOPS Positive symptoms in the Poisson analyses,
we established a classification of BASC Time 1 Atypicality Scale T ≥ 70 to determine the
sensitivity, specificity, positive predictive power (PPP), and negative predictive power (NPP)
of a Time 1 BASC Atypicality score in the ‘Clinical’ range towards predicting Time 2 positive
prodromal symptoms. Using this classification, the Time 1 BASC Atypicality T ≥ 70 had a
sensitivity of 43% and a specificity of 90%. The PPP of the Time 1 BASC Atypicality T ≥ 70
was .91%, indicating that if the Time 1 BASC Atypicality was greater than 70, there is 91%
likelihood that prodromal symptoms emerged at Time 2. The NPP of the Time 1 BASC
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Atypicality T ≥ 70 was found to be 42%, signifying a 42% chance that a participant deemed
‘non-clinical’ on the basis of the Time 1 BASC Atypicality will be non-prodromal at Time 2.
While these results demonstrate strong specificity and PPP of a BASC Time 1 Atypicality
Scale T ≥ 70 towards predicting Time 2 prodromal symptoms, the sensitivity and NPP of this
scale alone is less than ideal. Thus, to further guide clinicians, our sensitivity, specificity, PPP
and NPP statistics were recalculated using both a BASC Time 1 Atypicality Scale T ≥ 70 and
the highest cognitive predictor of the SOPS Positive symptoms, the WCST Nonperseverative
standard score one standard deviation below the mean (≤ 85). Using this combination of both
behavioral and cognitive measures, the sensitivity of predicting Time 2 prodromal symptoms
improved to 79% with a specificity of 95%. The PPP of 96% and NPP of 78% were similarly
improved.
Discussion
Psychiatric and Cognitive Functioning
Prodromal symptoms—While no adolescents with VCFS were diagnosed with a psychotic
disorder, significant prodromal psychotic symptoms were observed in approximately 20% of
our VCFS sample. This prevalence rate of prodromal psychotic symptoms is somewhat below
what others have reported (30–50%) 10, 42 and may be a function of our relatively strict criterion
for operationalizing prodromal symptoms.
Childhood performance on several tests of executive functioning and verbal abilities best
predicted prodromal symptom levels in adolescence. Across all tests, lower performance during
childhood predicted more prodromal symptoms in adolescence. This finding is entirely
consistent with other VCFS research 47 as well as the non-VCFS schizophrenia research 70–
83. Thus, our data are entirely consistent with the extant non-VCFS high risk data; language
and executive function deficits in childhood appear to presage which children with VCFS will
develop significant prodromal psychotic symptoms in adolescence.
Behaviorally, a child with VCFS who has high levels of odd/eccentric and anxious behaviors
may be at greatest risk of developing significant prodromal psychotic symptoms in
adolescence. Once again, this finding is entirely consistent with other VCFS longitudinal data
47 as well as the non-VCFS schizophrenia research 84–89.
While certainly needing replication, our data suggest that mental health clinicians working
with children with VCFS may wish to employ the BASC and WCST. A childhood BASC
Atypicality T ≥ 70 score alone had strong specificity (90%) and PPP (91%) yet when a WCST
Nonperseverative error (≤ 85) was added, the strong specificity and PPP were maintained and
the sensitivity improved to 79% and the NPP (78%) also improved. Adding the WCST to the
screening assessment improved the sensitivity and NPP suggesting that for maximal predictive
power, clinicians may wish to use both the BASC and WCST.
Internalizing disorders—Children with VCFS, as they aged into adolescence, were more
likely to be diagnosed with major depressive disorder and generalized anxiety disorder
diagnoses. Our prevalence rate of major depressive disorder (64%) is somewhat higher than
data recently published on a large cohort of individuals with VCFS 90. In that study, 40% of
late adolescents with VCFS were diagnosed with depression 90. In that same study, anxiety
disorders were the most common psychiatric diagnosis with prevalence rates ranging from 42–
60% depending on age 90. Our data (53%) are entirely consistent with these prevalence rates
and suggest that a majority of adolescents with VCFS will have a mood and/or anxiety disorder.
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Siblings of youth with VCFS were also more likely than controls to be diagnosed with major
depressive disorder in adolescence. No childhood cognitive or behavioral variables predicted
adolescent depression in the siblings. This is an interesting finding which requires replication.
However, it may be that growing up in a house with a child with VCFS is a chronically stressful
experience which can lead to depressed mood. Future research should consider how VCFS
affects the entire family system.
In the VCFS sample, child performance WISC-III processing speed and performance on a
nonverbal task of working memory (Visual Span Backwards) were both significant predictors
of adolescent depression in the VCFS group. Behaviorally, having high levels of anxiety, social
withdrawal as well as having poor social skills and an ADHD diagnosis appear to be predictive
of becoming depressed in adolescence. Other non-VCFS longitudinal research has similarly
suggested that childhood levels of anxiety and social withdrawal 91, 92 as well as an ADHD
diagnosis 93 all confer increased risk for depression in adolescence.
Cognitive functioning—While cross-sectional data 90 including our own work 5 suggest a
negative association between cognitive functioning and age, our longitudinal data suggest that
not all cognitive functions may be equally affected. Wechsler Full Scale IQ, Processing Speed
and Freedom from Distractibility indices all decreased significantly across age. CVLT
performance and math academic attainment also significantly dropped over time. Nonetheless,
performance on WCST Perseverative errors, Tower of London and reading attainment all
significantly improved as a function of age. Thus, it does not appear that all cognitive functions
decline as a function of age. Nonetheless, IQ scores have been traditionally used far more often
as an outcome measure than any of the other test (and were the only cognitive variable included
in the large cross-sectional study 90.
Also of interest is our finding that females with VCFS declined more than males with VCFS
across multiple psychological tests. This may help to explain the relatively inconsistent finding
in the literature; some research groups including our own have reported that males with VCFS
are more cognitively affected than females with VCFS 5, 94. Other groups, however, have failed
to report such sex differences 11, 95. It is possible that the age of the participants in the study
may be a factor which helps to explain this relatively inconsistent finding in the VCFS
literature.
COMT
Similar to others 47, our data suggest that the Val allele may be associated with greater
improvements across time in cognition; both groups improved yet the Val allele group
improved more. This is the opposite of what is typically reported in the non-VCFS population;
in both children 44 and adults 45, homozygosity for the Met allele is associated with optimal
cognitive function. It has been hypothesized that the Met allele is the risk allele in VCFS by
virtue of the inverted-U shape relationship between cortical dopamine signaling and cognitive
functioning 96. The inverted-U model proposes that either too little or too much D1 receptor
stimulation negatively affects cognitive functioning 97. Thus, it is hypothesized that individuals
with VCFS may be predisposed to cognitive dysfunction because they have the low activity
allele (Met).
Similar to others 49, 50, our results do not suggest a COMT effect on psychosis; while a higher
ratio of Met allele (26%) than Val allele (15%) had significant prodromal symptoms, this
difference was not statistically significant. Our results, however, are in the same general trend
as those from Gothelf and colleagues 47 who found a higher prevalence of psychotic symptoms
in their Met allele sample.
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Our data must be considered in the context of our methodological limitations. None of the
adolescents in our study met DSM-IV criteria for schizophrenia at Time 2. This may be partially
explained by the relatively young age (and that many of the participants with VCFS have not
yet entered the age when psychotic symptoms become more prevalent). Nonetheless, our
reliance on prodromal symptoms and not full DSM-IV schizophrenia criteria may be a
limitation. For example, there may not be a perfect correlation between prodromal symptoms
and eventual schizophrenia. Time 3 assessments, which are already underway in our research
program, will help to further determine the extent to which these Time 2 prodromal symptoms
will lead to eventual schizophrenia.
Despite our limitations, these data represent one of the very few longitudinal studies which
have attempted to predict psychotic symptoms in VCFS. In mid-adolescence, 20% of our VCFS
sample had significant prodromal psychotic symptoms. Major depressive disorder and
generalized anxiety diagnoses increased significantly in the VCFS sample. In our VCFS
sample, weaker executive functioning and verbal abilities and high levels of odd/eccentric and
anxious behaviors in childhood best predicted prodromal symptom levels in adolescence. The
child BASC Atypicality scale and WCST Nonperseverative errors were the two best predictors
of adolescent prodromal psychotic symptoms.
These data represent a good proof of concept study suggesting that the onset of prodromal
psychotic symptoms is predictable. Screening for future psychosis risk may someday be
possible, which would allow for preventive intervention programs to be developed. In fact, the
low false positive rate suggests that, although screening will not capture all future cases, the
child with VCFS who screens positive is likely to be true positives, which means that focusing
clinical resources on this group could be warranted.
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Table 4
Time 2 Scale of Prodromal Symptoms Descriptive Data
VCFS Siblings Controls
Positive Symptoms 1.3 (2.9) *** 0.0 (0.2) 0.4 (1.2)
Negative Symptoms 2.0 (3.7) ** 0.3 (0.8) 0.9 (1.7)
Disorganized Symptoms 1.0 (2.4) *** 0.1 (0.5) 0.1 (0.5)
SOPS Total 4.2 (7.7) ** 0.4 (1.2) 1.3 (2.8)
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Table 5




WCST Perseverative Errors Standard Score − 2.59 .010
Visual Span Backward − 6.86 .000
Visual Span Forward − 3.19 .001
Stroop Color-Word Interference T-Score − 2.59 .010
WISC-III Processing Speed Index − 3.67 .000
WISC-III Verbal Comprehension Index − 3.81 .000
Behavioral/Psychiatric
BASC Atypicality 2.82 .005
BASC Anxiety 2.79 .005
CGAS − 4.94 .000
PAS 4.57 .000
Note. WCST = Wisconsin Card Sorting Test. WISC-III = Wechsler Intelligence Scale for Children – 3rd edition. BASC = Behavioral Assessment
Scales for Children. CGAS = Clinician Rated Global Assessment Scale. PAS = Premorbid Adjustment Scale.
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